Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00998192 · ClinicalTrials.gov registry record · Phase 2
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
A Phase 2 study, sponsored by Oncolytics Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00998192: Completed Phase 2 study, sponsored by Oncolytics Biotech.
NCT00998192 is a Phase 2 study that has completed, run by Oncolytics Biotech. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00998192, a Phase 2 study, has completed, sponsored by Oncolytics Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic reovirus in combination with paclitaxel and carboplatin is effective and safe in the treatment of squamous cell carinoma of the lung.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL REOLYSIN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2009-10 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
What the finished NCT00998192 record still lists
NCT00998192 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00998192 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00998192 about?
NCT00998192 is a clinical study titled "A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung". The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic reovirus in combination with paclitaxel and carboplatin is effective and safe in the treatment of squamous cell carinoma of the lung.
What is the current status of trial NCT00998192?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2009-10. Estimated completion is 2015-08.
What interventions are being tested in trial NCT00998192?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), REOLYSIN (BIOLOGICAL).
Who is sponsoring clinical trial NCT00998192?
This trial is sponsored by Oncolytics Biotech, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00998192's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia